Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365207 · ClinicalTrials.gov registry record · NA
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02365207 is a NA study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 6 participants.
The verdict
NCT02365207, a NA study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
Interventions
- DRUG BCG strain of Mycobacterium bovis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-11 |
| Est. Completion | 2019-04-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365207
The ClinicalTrials.gov registry entry for NCT02365207 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BCG strain of Mycobacterium bovis is the first listed.
NCT02365207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365207 about?
NCT02365207 is a clinical study titled "Intravesical BCG Administration to Patients With Invasive Bladder Cancer". Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.
What is the current status of trial NCT02365207?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2013-11. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT02365207?
The interventions under investigation include: BCG strain of Mycobacterium bovis (DRUG).
Who is sponsoring clinical trial NCT02365207?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.